What is Innovate's other long-term liabilities?

Innovate (VATE) reported other long-term liabilities of -$5M in Q1 2026.

How has Innovate's other long-term liabilities changed year-over-year?

Innovate's other long-term liabilities decreased by 25.0% year-over-year, from -$4M to -$5M.

Over 4 years (2021 to 2025), Innovate's other long-term liabilities has grown at a 5.9% compound annual growth rate (CAGR), from -$10.9M to -$13.7M.

Foster (Lb) Co.FSTR

——

AnterixATEX

——

Revenue$364.8M+33.0%

Gross profit$53.5M+17.6%

Operating income$10.0M+194%

Net income-$16.8M+31.4%

EPS (diluted)-$1.29+31.7%

Cash & equivalents$134.6M+297%

Total debt$1.4B+11.6%

Total equity-$256.3M-25.5%

Total assets$936.8M+7.9%

Operating cash flow$45.5M+423%

CapEx$200.0K-95.7%

Free cash flow$45.3M+341%

Market cap$254.69M+274%

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Innovate's other long-term liabilities?: Innovate (VATE) reported other long-term liabilities of -$5M in Q1 2026.
How has Innovate's other long-term liabilities changed year-over-year?: Innovate's other long-term liabilities decreased by 25.0% year-over-year, from -$4M to -$5M.
What is the long-term trend for Innovate's other long-term liabilities?: Over 4 years (2021 to 2025), Innovate's other long-term liabilities has grown at a 5.9% compound annual growth rate (CAGR), from -$10.9M to -$13.7M.